SCIENTECH (02291) surged nearly 10% in afternoon trading, rising 8.43% to HK$27 with turnover reaching HK$27.50 million as of press time.

The medical device company released its interim results showing revenue of RMB 330 million, representing a 32.4% year-over-year increase. Net profit attributable to shareholders reached RMB 182 million, up 29.8% compared to the same period last year. Basic earnings per share stood at RMB 0.5249.

As of the announcement date, SCIENTECH has a total of 30 marketed occluder, heart valve and accessory products, along with 4 products under registration review or preparation. The company also maintains a robust pipeline of 28 products at various development stages, including occluders, heart valves, surgical accessories, and mechanical circulatory support devices.

CITIC Securities highlighted that SCIENTECH has comprehensive coverage in the structural heart disease field, with its product pipeline spanning congenital heart defect occluders, stroke prevention, valves, and heart failure treatment areas. The company's valve portfolio is particularly rich, with its TAVR product already approved for market. In the aortic and peripheral occluder segment, SCIENTECH has positioned itself in biodegradable aortic occluders.

The brokerage noted that the company has maintained rapid performance growth in recent years, primarily benefiting from the volume expansion of new products such as biodegradable occluders. SCIENTECH's biodegradable occluder technology currently holds a leading position globally with proprietary intellectual property rights. The technology has potential for overseas expansion through either direct sales or business development partnerships. Considering the high costs of overseas clinical development and the company's technological leadership, this product series demonstrates strong overseas licensing-out potential.